Skip to main content

Table 3 Treatment response of enrolled patients

From: Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy

Response

No. of patients

Percent

Complete response

-

-

Partial response

0

0%

Stable disease

4

40%

Progressive disease

4

40%

Not available

2

20%

Overall response rate

0%

Disease control rate

30%